SMA Foundation

Jun 12, 2020

PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy

Apr 28, 2020

Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy

Apr 07, 2020

PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)

Feb 06, 2020

SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

Mar 19, 2019

SMA Treatment Market Size Worth $3.9 Billion by 2025 | CAGR 12.9%: Grand View Research, Inc.

Jun 16, 2018

Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference

Mar 15, 2018

FIREFISH Transitions into Pivotal Phase

Jan 27, 2018

Preliminary Data from FIREFISH trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy

Oct 12, 2017

Spinal Muscular Atrophy Program Advances into Pivotal Study in SMA Patients

Oct 03, 2017

RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy